You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)上半年研發支出6.6億元 約200個創新項目
阿思達克 11-19 12:30

華潤醫藥(03320.HK)公布,已涵蓋心腦血管、抗腫瘤、呼吸科、兒科、神經科、抗感染、消化科、皮膚科及感冒止咳等治療領域,今年共生產超過540種產品,其中超過300種產品進入了國家醫保目錄,139個產品在基藥目錄內。去年銷售規模超過10億港元的產品有7個,過億港元的產品有49個。公司並累計組建了數千人的專業化銷售推廣團隊,目前建立了與6,800多家等級醫院和超過11萬基層醫療機構的長期深入業務合作關係。

今年上半年公司研發支出共計6.6億港元,按人民幣計按年增加7.9%。6月底止共有各類研發創新項目約200個,其中創新藥在研項目45個。公司上半年引進多個具有臨床價值和市場價值的在研品種,涉及眼科、新陳代謝、抗腫瘤和胃腸道等領域,其中包括5個1類化學創新藥及一個生物類似藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account